Detection of CJC-1295 in Equine Plasma by ELISA.
The study developed an ELISA that can detect CJC-1295 in equine plasma at very low concentrations, which may help in anti-doping efforts.
Where it sits
this study against the rest of the cjc-1295 corpusSummary and findings
CJC-1295 was detected in equine plasma using an ELISA developed with monoclonal antibodies. The assay was effective at detecting concentrations as low as 12.5 pg/mL following subcutaneous administration of 10 mg of CJC-1295. The study focused on its potential use in controlling illicit doping in thoroughbred racehorses.
Abstract
CJC-1295 is a peptide-based drug that stimulates the endogenous production of growth hormone (GH). Compared to other growth hormone releasing hormone (GHRH) analogues, CJC-1295 has an extended half-life due to a drug affinity complex (DAC) that chemically crosslinks the peptide to plasma proteins containing free cysteine residues. As a result, CJC-1295 behaves more like a protein doping agent than a typical peptide-based drug. Using monoclonal antibodies raised against the CJC-1295 peptide, an ELISA was developed for the detection of CJC-1295 protein conjugates in equine plasma at concentrations as low as 12.5 pg/mL. The effectiveness of the assay for controlling the illicit use of CJC-1295 was demonstrated using equine blood samples, obtained from thoroughbred racehorses, following subcutaneous administration of 10 mg of CJC-1295.
Background
This study addresses the detection of CJC-1295, a peptide that stimulates endogenous growth hormone production, in equine plasma. Prior knowledge indicated that CJC-1295 has an extended half-life due to its chemical structure, which allows it to behave similarly to protein doping agents. The development of a reliable detection method is crucial for monitoring its illicit use in competitive sports, particularly in thoroughbred racing.
Methods
The study utilized an ELISA developed with monoclonal antibodies specific to CJC-1295. The population consisted of thoroughbred racehorses, and the peptide was administered subcutaneously at a dose of 10 mg. The primary outcome measure was the ability to detect CJC-1295 in plasma samples.
Results
The assay successfully detected CJC-1295 in equine plasma at concentrations as low as 12.5 pg/mL. The study demonstrated the effectiveness of the assay in controlling the illicit use of CJC-1295 in equine athletes.
Interpretation
The findings indicate that the ELISA can effectively detect CJC-1295 in equine plasma, which is significant for anti-doping efforts. However, the clinical implications for human use remain unclear, and the study's focus on equine subjects limits generalizability. The detection limit of 12.5 pg/mL suggests a sensitive assay, but further validation in diverse populations is necessary.
Key findings
- Detection of CJC-1295 in equine plasma at concentrations as low as 12.5 pg/mL.
- Subcutaneous administration of 10 mg of CJC-1295 was used in the study.
Limitations
- Not reported in abstract.